Logo

American Heart Association

  56
  0


Final ID:

TAVR with Leaflet Modification: Worth the Trouble?

  • Dvir, Danny  ( SZMC , Jerusalem , Israel )
  • Khan, Jaffar  ( NHLBI , Bethesda , Maryland , United States )
  • Lederman, Robert  ( NHLBI , Bethesda , Maryland , United States )
  • Greenbaum, Adam  ( Emory , Atlanta , Georgia , United States )
  • Author Disclosures:
    Danny Dvir: No Answer | Jaffar Khan: DO have relevant financial relationships ; Consultant:Abbott:Active (exists now) ; Royalties/Patent Beneficiary:Assigned to NIH on leaflet modification devices:Active (exists now) ; Individual Stocks/Stock Options:Cuspa Medical:Active (exists now) ; Individual Stocks/Stock Options:Transmural Systems:Active (exists now) ; Consultant:Medtronic:Active (exists now) ; Consultant:Edwards Lifesciences:Active (exists now) | Robert Lederman: DO NOT have relevant financial relationships | Adam Greenbaum: DO have relevant financial relationships ; Consultant:Edwards Lifesciences:Active (exists now) ; Consultant:Emboliner:Active (exists now) ; Consultant:Polares:Active (exists now) ; Individual Stocks/Stock Options:Excision Medical:Active (exists now) ; Individual Stocks/Stock Options:Transmural Systems:Active (exists now) ; Speaker:Abbott:Active (exists now) ; Consultant:Medtronic:Active (exists now)
Meeting Info:

Scientific Sessions 2025

2025

New Orleans, Louisiana

More abstracts on this topic:
Case Presentation: Acute Coronary Syndrome in a Patient with h/o TAVR

Wang Hanghang, Hamilton Barbara

Debate: M-TEER Following TAVR the Safest Choice!

Szerlip Molly, Tang Gilbert, Rogers Jason, Mccabe James

More abstracts from these authors:
You have to be authorized to contact abstract author. Please, Login
Not Available